Navigation Links
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Date:2/20/2013

RIDGEFIELD, Conn., Feb. 20, 2013 /PRNewswire/ -- New findings from two double-blind, randomized trials, RE-MEDYSM and RE-SONATE®, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE)*. The results were published today in the New England Journal of Medicine.

VTE is the third most common cardiovascular disorder after heart disease and stroke, and consists of two related conditions caused by blood clots: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is when a blood clot develops in the deep veins of the leg or pelvis. The clot, or part of it, can break off from the site where it formed and travel through the veins (embolism). A PE can occur if the clot lodges in the arteries of the lungs.

There are an estimated 900,000 VTE events per year in the U.S., approximately one-third of which result in death from PE. Further, roughly one-third of people with VTE will have a recurrence within 10 years. The standard of care for patients with VTE is anticoagulation.

RE-MEDY demonstrated that treatment with dabigatran 150 mg twice daily was non-inferior to warfarin (p=0.01) in preventing recurrent VTE, including VTE-related death. RE-SONATE demonstrated dabigatran was superior to placebo for the prevention of first recurrent or fatal VTE with a risk reduction of 92 percent during the treatment period (p<0.001). Lower event rates were reported across all secondary efficacy endpoints for dabigatran over placebo.

"Patients who suffer one VTE event are at increased risk of suffering another, with the risk accumulating over time," said Sam Schulman , M.D., Ph.D., FRCPC(C), lead study author and professor, Department of Medicine, McMaster University, Ontario, Canada. "We are encouraged to see that the RE-MEDY and RE-SONATE trials met their endpoints and we will continue to study the safety, efficacy and p
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014  Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ... European Commission (the "EC") to extend the deadline for ... by a limited number of days in order to ... Deadline extensions are not uncommon in such in-depth ... authorities to facilitate their review of the pending transaction ...
(Date:11/18/2014)... Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced today that ... 2014 at 9:00 a.m. Eastern Time to discuss the ISIS-FXI ... Society of Hematology Annual Meeting and Exposition.  ... or access the webcast at www.isispharm.com .  A webcast ... same address. ABOUT ISIS PHARMACEUTICALS, INC. ...
(Date:11/18/2014)... 18, 2014  AgeneBio, a pharmaceutical company developing ... restore brain function, today announced that the Company,s ... , PhD, has received the Society for Neuroscience,s ... 35 years, Dr. Gallagher,s research at Johns Hopkins ... Hill has led to advancements in the field ...
Breaking Medicine Technology:Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 2Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 3Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 4Zimmer Provides Update on the European Commission Review Process Relating to the Pending Merger with Biomet, Inc. 5Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 2Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 3AgeneBio Founder and Chief Scientific Officer Receives Society for Neuroscience's Mika Salpeter Lifetime Achievement Award 2AgeneBio Founder and Chief Scientific Officer Receives Society for Neuroscience's Mika Salpeter Lifetime Achievement Award 3
(Date:11/18/2014)... 18, 2014 A+ Secure Packaging, ... nutraceutical, dietary supplements and more, announced today that ... Good Manufacturing Practices (GMP) Registration for dietary supplements ... from NSF International verifies the A+ Secure Packaging ... compliance requirements of its clients by demonstrating the ...
(Date:11/18/2014)... Newport Beach, CA (PRWEB) November 18, 2014 ... settle into new routines, many people look at fall ... the holidays. Dr. Kevin Sadati , Orange County ... at this Newport Beach practice. At the Gallery ... his patients taking advantage of his non-invasive cosmetic surgery ...
(Date:11/18/2014)... Haelle HealthDay Reporter MONDAY, ... experience a severe abusive head trauma before the age of ... new study. In addition, among those who survive ... the study found. Abusive head trauma includes shaken baby ... suffers head injuries, according to background information in the study. ...
(Date:11/18/2014)... HealthDay Reporter , MONDAY, Nov. 17, ... not have significant heart-health benefits for older people, new ... than 14,000 Japanese people aged 60 to 85, found ... attacks and strokes between people who took aspirin and ... prevention with daily low-dose aspirin does not reduce the ...
(Date:11/18/2014)... Dennis Thompson HealthDay ... Heart attack and stroke patients can safely take aspirin combined ... blood-thinning combination won,t increase a patient,s risk of early death, ... meeting of the American Heart Association in Chicago. The report ... . Analysis of data from more than a dozen ...
Breaking Medicine News(10 mins):Health News:A+ Secure Packaging, LLC Earns NSF International Good Manufacturing Practices (GMP) Registration for Dietary Supplements and Certification for Sport 2Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 2Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 4Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 3Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3
... News) -- Many children who,ve lost a sister or brother ... as a result of the experience, new research finds. ... Nursing , researchers from Nationwide Children,s Hospital in Columbus, Ohio, ... a sibling impacted them one year later. Siblings were ...
... New breast cancer screening guidelines for women at ... (Canadian Medical Association Journal) (pre-embargo link only) ... women aged 40-49 and extend the screening interval ... practice, to every 2 to 3 years for ...
... 2011) -- Older adults receiving home health care may be ... their age. In fact, nearly 40 percent of seniors receiving ... least one prescription medication that is considered potentially inappropriate to ... Internal Medicine has revealed. The study,s researchers, led ...
... find the main culprit behind the dry, irritated eyes, ... of the population., It,s called Sjgren,s syndrome, a painful ... 6.5 years to diagnose and is difficult to treat. ... how it develops should improve diagnosis and treatment. , ...
... of Michigan Medical School and MedImmune, the global biologics ... work together on a broad range of projects. ... of the nation,s top medical research institutions together with ... biologic therapies. UMMS and MedImmune scientists will ...
... Institutet have developed a new method for counting molecules. ... DNA molecules is a fundamental task in molecular biology ... in cells. Thus, improved measurement techniques are crucial for ... very difficult to detect small individual molecules in a ...
Cached Medicine News:Health News:Siblings Deeply Affected By Child's Cancer Death 2Health News:New breast cancer screening guidelines released 2Health News:New breast cancer screening guidelines released 3Health News:Older adults in home health care at elevated risk for unsafe meds 2Health News:Researchers search for culprit behind dry eyes, mouths and more 2Health News:Researchers search for culprit behind dry eyes, mouths and more 3Health News:U-M Medical School and MedImmune join forces to accelerate search for new therapies 2Health News:A better way to count molecules discovered 2
The PillCam™ ESO video capsule is specifically designed to view the inner lining of the Esophagus. The capsule is equipped with miniature cameras on both ends and is about the size of a multi-v...
... Radi invented the guidewire-mounted pressure ... way. PressureWire5 Sensor is the only ... pressure, temperature and flow. With significantly ... serves as your primary guidewire, as ...
... ultrasound and MRI-guided vacuum assisted breast biopsies ... the patented, FDA-cleared ATEC system for a ... method of breast biopsy. Its compassionate care ... trust YOU.,9 Gauge Handpieces: Useful for biopsy ...
Three-spring evacuator kits with silicone drains, 10 in. hole pattern, trocar and Y-connector tubing...
Medicine Products: